Beijing Airdoc Technology completed its global offering and listing on the Hong Kong Stock Exchange, raising $215 million (which could rise to $247 million if a greenshoe option is exercised in full).
Airdoc provides AI-empowered, retina-based diagnosis and health risk assessment solutions in China. Its core product, Airdoc-AIFUNDUS (1.0), is a software as a medical device for auxiliary diagnosis of diabetic retinopathy. This product was the first of its kind to obtain the Class III medical device certification from the National Medical Products Administration of the PRC.
S&C acted for the underwriters, including UBS, CLSA, CMBI, Essence, Haitong, China PA, Fosun Hani, GF, Guodu, SPDBI, Futu, US Tiger and uSmart on both Hong Kong and U.S. law matters.
The S&C team was led by Kay Ian Ng and Ching-Yang Lin in Hong Kong, and Gwen Wong in Beijing.
Subscribe to stay current on S&C Insights.
Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.